Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Via Orphan Drug Grant Program, FDA Funds New ALS Research

The U.S. Food and Drug Administration (FDA) is funding several novel research projects related to amyotrophic lateral sclerosis (ALS) and other rare neurological disorders through its orphan drug grants program. In total, the regulatory agency has awarded 19 new grants and two contracts, providing more than $38 million…

Review Finds ‘No Strong Evidence’ Linking Medicines With ALS Risk

There is no compelling evidence to suggest any medication increases the risk of developing amyotrophic lateral sclerosis (ALS), according to a review of published studies. If anything, classes of drugs including anti-hypertensives, cholesterol-lowering statins, aspirin, and oral contraceptives may be associated with a lower risk of ALS, although several…

Early Tofersen Treatment May Help to Slow SOD1-ALS Progression

Early treatment with Biogen’s experimental therapy tofersen slows disease progression in people with amyotrophic lateral sclerosis (ALS) associated with SOD1 gene mutations, compared with patients who started treatment after a six-month delay, according to findings from a Phase 3 trial and its open-label extension study. These benefits…

PrimeC Safe, Lowers ALS Disease Biomarkers in Phase 2 Clinical Study

PrimeC, an experimental combination treatment for amyotrophic lateral sclerosis (ALS) being developed by NeuroSense Therapeutics, was well tolerated and lowered disease biomarkers in an open-label Phase 2 clinical trial. That’s according to the study, “Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS,” published…

AMX0035 Alters Activity of Various Genes Relevant to ALS, Study Finds

AMX0035 — Amylyx Pharmaceuticals’ experimental combination therapy for amyotrophic lateral sclerosis (ALS) now under review for approval in the U.S. — alters the activity of genes involved in several disease-relevant pathways, according to a study in lab-grown cells. Notably, the two-compound oral treatment was seen to change the activity of many…